Local Institution - New York 1
1 Park Avenue
New York, New York 10016
New York, New York 10016
We've found
1 trials
at this facility
Oncology Clinical Trial
Updated: 12/31/1969
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
